NCT06382688

IV Administration of ChromaDex's Niagen® as Compared to NAD+

The Effects of IV Administration of ChromaDex's Niagen®, Nicotinamide Riboside Chloride as Compared to IV Administration of NAD+: A Randomized, Placebo Controlled Clinical Trial

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 53 (actual)
• Sponsor: Nutraceuticals Research Institute · Academic / Other
• Sex: All
• Age: 40 Years
• Healthy volunteers: Accepted

Summary

This is a 2-part study evaluating the effects of IV administration of NR on healthy adult populations. Study 1 involved all four arms with 37 people. The second study only included the active NR and NAD+ arms to further evaluate tolerability and comfort of the IV.

Detailed description

The purpose of this work is to establish and quantify the safety and efficacy of IV administration of ChromaDex's Niagen®, nicotinamide riboside chloride in comparison to currently available IV NAD+, a saline IV, and orally administered Niagen®

Conditions

• Healthy Aging

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	NAD+ (nicotinamide adenine dinucleotide) IV	NAD+ enables cells to generate cellular energy from the food that one eats
DIETARY_SUPPLEMENT	Niagen® (nicotinamide riboside) IV	NR is a unique member of the vitamin B3 family. Cells can use NR to create nicotinamide adenine dinucleotide (NAD+), which is an essential molecule found in every living cell. Patients in this arm received an IV administration.
DIETARY_SUPPLEMENT	Niagen® (nicotinamide riboside) oral	NR is a unique member of the vitamin B3 family. Cells can use NR to create nicotinamide adenine dinucleotide (NAD+), which is an essential molecule found in every living cell. Patients in this arm received an oral administration.
OTHER	Placebo	These individuals received a saline IV

Timeline

• Start date: 2023-11-13
• Primary completion: 2024-03-08
• Completion: 2024-08-31
• First posted: 2024-04-24
• Last updated: 2024-04-24

Locations

1 site across 1 country: United States